The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic melanoma (mM).
Omid Hamid
Consultant or Advisory Role - Genentech
Honoraria - Genentech
Research Funding - Genentech
Jeffrey Alan Sosman
Consultant or Advisory Role - Roche
Honoraria - Roche
Research Funding - Roche
Donald P. Lawrence
No relevant relationships to disclose
Ryan J. Sullivan
No relevant relationships to disclose
Nageatte Ibrahim
No relevant relationships to disclose
Harriet M. Kluger
Consultant or Advisory Role - Genentech
Peter D. Boasberg
Research Funding - The Angeles Clinic
Keith Flaherty
Consultant or Advisory Role - Roche
Patrick Hwu
No relevant relationships to disclose
Marcus Ballinger
Employment or Leadership Position - Genentech
Stock Ownership - Roche
Ahmad Mokatrin
Employment or Leadership Position - Genentech
Stock Ownership - Genentech/Roche
Marcin Kowanetz
Employment or Leadership Position - Genentech
Stock Ownership - Roche
Daniel S. Chen
Employment or Leadership Position - Genentech
Stock Ownership - Genentech/Roche
F. Stephen Hodi
Consultant or Advisory Role - Genentech (U)
Research Funding - Genentech